Focused On-demand Library for Nuclear receptor subfamily 4 group A member 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q92570

UPID:

NR4A3_HUMAN

Alternative names:

Mitogen-induced nuclear orphan receptor; Neuron-derived orphan receptor 1; Nuclear hormone receptor NOR-1

Alternative UPACC:

Q92570; A2A3I7; Q12935; Q14979; Q16420; Q4VXA8; Q4VXA9; Q9UEK2; Q9UEK3

Background:

Nuclear receptor subfamily 4 group A member 3 (NR4A3), also known as Neuron-derived orphan receptor 1, plays a pivotal role in various cellular processes including proliferation, survival, differentiation, metabolism, and inflammation. It functions by binding to specific DNA sequences, regulating gene expression in response to physiological stimuli. NR4A3's involvement in cell cycle regulation and survival, particularly in vascular smooth muscle and neuronal cells, underscores its biological significance.

Therapeutic significance:

NR4A3's link to Ewing sarcoma, a highly malignant tumor affecting children and adolescents, highlights its therapeutic potential. The protein's role in disease pathogenesis, driven by chromosomal aberrations, opens avenues for targeted therapies. Understanding NR4A3's function could lead to innovative treatments for Ewing sarcoma and possibly other NR4A3-related conditions.